Skip to main navigation Skip to search Skip to main content

Case Commentary: When one target is not enough—PBP3 insertions and target redundancy in Escherichia coli

Research output: Contribution to journalReview articlepeer-review

Abstract

This challenging clinical case highlights the impact of PBP3 insertions in Escherichia coli, which reduce susceptibility to key β-lactam agents and complicate treatment, particularly in the setting of NDM production (C. Fabrizio, F. Valzano, S. Giuliano, E. Morelli, et al., Antimicrob Agents Chemother 70:e00887-25, 2026, https://doi.org/10.1128/aac.00887-25). Clinical improvement was achieved with imipenem–relebactam plus aztreonam, supporting the idea that targeting multiple penicillin-binding proteins can overcome functional redundancy. These findings emphasize the clinical relevance of PBP3-mediated resistance and the need for treatment strategies that address complex β-lactam resistance in Gram-negative pathogens.

Original languageEnglish
JournalAntimicrobial agents and chemotherapy
Volume70
Issue number5
DOIs
Publication statusPublished - 05-2026
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Case Commentary: When one target is not enough—PBP3 insertions and target redundancy in Escherichia coli'. Together they form a unique fingerprint.

Cite this